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Abstract Primary central nervous system (CNS) tumors
cause significant morbidity and mortality in both adults and
children. While some of the genetic and molecular
mechanisms of neuro-oncogenesis are known, much less
is known about possible epigenetic contributions to disease
pathophysiology. Over the last several decades, chronic
viral infections have been associated with a number of
human malignancies. In primary CNS malignancies, two
families of viruses, namely polyomavirus and herpesvirus,
have been detected with varied frequencies in a number of
pediatric and adult histological tumor subtypes. However,
establishingalinkbetweenchronicviralinfectionandprimary
CNS malignancy has been an area of considerable controver-
sy, due in part to variations in detection frequencies and
methodologies used among researchers. Since a latent viral
neurotropism can be seen with a variety of viruses and a
widespread seropositivity exists among the population, it has
been difficult to establish an association between viral
infection and CNS malignancy based on epidemiology alone.
While direct evidence of a role of viruses in neuro-
oncogenesisinhumansislacking,amoreplausiblehypothesis
of neuro-oncomodulation has been proposed. The overall
goals of this review are to summarize the many human
investigationsthathavestudiedviralinfectioninprimaryCNS
tumors, discuss potential neuro-oncomodulatory mechanisms
of viral-associated CNS disease and propose future research
directions to establish a more firm association between
chronic viral infections and primary CNS malignancies.
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Introduction
Primary central nervous system (CNS) tumors occur at an
incidence of 16.5 cases/100,000 person-years, of which
approximately 27% represent children less than 19 years
old (CBTRUS 2009). Primary CNS tumors occur more in
men (3.7/100,000 person-years) than in women (2.6/
100,000-person-years; GLOBOCAN 2002; Parkin et al.
2002) and are composed of a diverse set of histological and
biochemical features, each associated with its own morbidity
and mortality despite multimodality treatment with surgery,
radiation, chemotherapy, and biologic approaches. In the
USA, the mortality rates for primary malignant brain tumors
ranges from 3.7–5.6 per 100,000 with 25–29% 5 and 10-year
survival, respectively, according to American Cancer
Society statistics (http://www.cancer.org/statistics/). In terms
of epidemiologic etiologies of primary brain tumors, many
potential risk factors have been studied including genetic
susceptibility (genetic syndromes or gene-specific polymor-
phisms), radiation exposure (ionizing and non-ionizing
electromagnetic fields), neuro-carcinogens, allergic diseases,
and viral infections (Wrensch et al. 2002; Bondy et al. 2008).
Since viral infections have been associated with other
systemic human malignancies including hepatitis B/C
(hepatocellular carcinoma), Epstein Barr virus (EBV;
B+T cell lymphoma, post-transplant lymphoproliferative
disease, leiomyosarcoma, nasopharyngeal carcinoma),
human papillomavirus (cervical carcinoma), human
herpesvirus-8 (HHV-8; Kaposi sarcoma), and human T
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DOI 10.1007/s11481-010-9204-0cell lymphotropic virus type 1 (T cell leukemia), it is not
unreasonable to hypothesize a role for viral infections in
CNS malignancies (Liao 2006). With regards to viral
etiologies of primary CNS tumors, the polyomavirus and
herpesvirus families have been among the most widely
studied. Over the past few decades, the interest in the
polyomavirus family of viruses has grown in parallel to
both the viruses’ association with human brain tumors and
oncogenecity in experimental animals (Croul et al. 2003;
White et al. 2005;A h s a na n dS h a h2006; Jiang et al.
2009). Among the members of the polyomavirus family,
the three that have been detected most widely in both
pediatric and adult histological subtypes of primary CNS
brain tumors are the JC virus (JCV), BK virus (BKV), and
Simian vacuolating virus 40 (SV40; Croul et al. 2003;
White et al. 2005; Barbanti-Brodano et al. 2006; Lee and
Langhoff 2006). The more recently discovered members
of the polyomavirus family (KI, WU, and MC) have yet to
be studied in association with human brain tumors (zur
Hausen 2008; Dalianis et al. 2009). The polyomavirus
family is of considerable interest in its potential role in
neuro-oncogenesis since it has been shown to induce brain
tumors in animal models (Rollison et al. 2003;R o l l i s o n
2006). The herpesvirus family is a functionally and structur-
ally diverse group consisting of eight known human variants
(herpes simplex 1-2; varicella zoster virus, Epstein Barr,
human cytomegalovirus, human herpesviruses 6, 7, and 8)
and has been associated with a number of human diseases
(Arvin et al. 2007). Since many of the herpesviruses can
establish lifelong latency in the CNS, whereby only a limited
number of viral genes are expressed without production of
progeny virions and lytic infection, it is plausible to
hypothesize that herpesviruses, among others, may play a
role in CNS neuro-oncogenesis. In this comprehensive
review of chronic viral infections and primary CNS
malignancy, we hope to summarize the numerous published
results both in support and in contradictory to the role of
chronic viral infection in human primary CNS malignancies.
Furthermore, we would like to address potential neuro-
oncologic molecular mechanisms of disease related to the
specific viruses reported in CNS tumors. Finally, we hope to
address the many controversies and propose future research
directions that promote a greater understanding of neuro-
virology in the area of neuro-oncology research.
Detection of human herpesviruses in primary CNS
malignancy
Herpes simplex 1, 2
Human herpes simplex viruses 1 and 2 (HSV-1/2),
members of the alphaherpesvirus family of DNA
viruses, are between 152–154 kbp (McGeoch et al.
1988; Dolan et al. 1998). HSV-1/2 infection is most
notable for its role in CNS encephalitis (Kimberlin 2006).
Surprisingly, most of the data on HSV-1/2 infection and
primary CNS tumors comes from serological IgG anti-
body studies by enzyme-linked immunosorbent assay as
summarized in Table 1. Between 79.6–82% of patients
with glioblastoma multiforme (GBM) were seropositive
for HSV-1/2 compared with 58–72% of other tumor brain
tumor types and 76.1–79.6% of non-tumor controls
(Wrensch et al. 2001, 2005). A high percentage of
seropositivity (86%) has also been reported in a series
of 72 primary CNS glioma, meningioma, and acoustic
schwanomma (Poltermann et al. 2006). Viral nucleic acid
detection of HSV-1/2 by real-time quantitative PCR
revealed 2.8% positivity in low-grade pilocytic astrocy-
tomas (N=35; Neves et al. 2008). Only a small number of
primary CNS tumors have been tested for HSV-1/2 by in
situ hybridization (ISH), and all have been negative
(Cobbs et al. 2002). To our knowledge, there has not
been a detailed immunohistochemistry (IHC) analysis
performed on a series of primary CNS tumors to assess
for HSV-1/2 viral antigen.
Varicella zoster virus
V a r i c e l l az o s t e rv i r u s( V Z V ) ,a n o t h e rm e m b e ro ft h e
alphaherpesvirus family, is smaller in size than HSV-1/2
and exhibits neuronal latency (Davison and Scott 1986).
VZV DNA has been detected in 5.7% of pilocytic
astrocytoma (2/35) compared with 0/10 non-tumor control
brain and without IHC correlate (Table 1). The more
interesting data on the role of VZV and primary CNS
tumors comes from epidemiologic studies comparing the
frequency of serum IgG positivity in GBM, other brain
tumor subtypes, and non-brain tumor controls. Wrensch et
al. first demonstrated an inverse correlation between VZV
IgG positivity in brain tumors (56/78) and non-tumor
controls (73/89) (Wrensch et al. 1997). The observed
findings in GBM were reproduced in a subsequent study
and revealed 38/46 anti-VZV IgG positive versus 137/
139 non-brain tumor control sera (Wrensch et al. 2001).
A third larger study revealed no changes in the degree of
anti-VZV IgG positivity between GBM and non-tumor
sera (109/115 vs. 282/289), however when stratifying
based on viral titer quartile, the inverse relationship was
maintained (Wrensch et al. 2005). While the authors
mention that these findings could be related to the
exclusion of patients on high-dose corticosteroids, the
trends are reproducible and are worthy of a larger multi-
institutional analysis to explore the possibility of a
“neuroprotective effect” of VZV immunoglobulin detection
in GBM.
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Herpesvirus
subtype
Tumor histology subtypes Serum viral IgG antibody detection
(ELISA)
Viral nucleic acid detection (PCR,
nPCR, qPCR, ISH)
Viral protein detection (IHC) Reference
HHV 1-2
(HSV1/2)
GBM (N=45), other glial
subtypes (N=43)
37/45 GBM+ 25/43 other glial
subtypes+ 90/113 non-tumor
controls+
NP NP Wrensch et
al. 2001
GBM (N=113), other brain
tumor subtypes (N=111)
90/113 GBM+ 79/111 other brain
tumor subtypes +, 217/285 non-
tumor controls +
NP NP Wrensch et
al. 2005
Pilocytic astrocytoma (N=35) NP 1/35 Pilocytic astrocytoma +, 2/10
non-tumor control+ by qPCR
NP Neves et
al. 2008
Glial tumors (N=35),
meningiomas (N=31)
acoustic schwanommas
(N=6)
62/72 Total tumors+ NP NP Poltermann
et al.
2006
GBM (N=3) diffuse fibrillary
astrocytoma (N=2)
NP 0/3 GBM+, 0/2 diffuse fibrillary
astrocytoma+, 0/3 normal brain
+ by ISH
NP Cobbs et
al. 2002
HHV-3
(VZV)
Glial tumors (N=78) 56/78 Glial tumors+, 73/89 non-
brain tumor controls+
NP NP Wrensch et
al. 1997
GBM(N=46) other brain tumor
subtypes (N=68)
38/46 GBM+, 63/68 other brain
tumor subtypes+, 137/139 non-
brain tumor controls+
NP NP Wrensch et
al. 2001
GBM (N=115), other brain
tumor subtypes (N=114)
109/115 GBM+, 110/114 other
brain tumor subtypes+, 282/289
non-brain tumor control +
NP NP Wrensch et
al. 2005
Pilocytic astrocytoma (N=35) NP 2/35 Pilocytic Astrocytoma+, 0/
10 Non-Tumor Control+ by
qPCR
NP Neves et
al. 2008
Glial tumors (N=35),
meningiomas (N=31)
acoustic schwanommas
(N=6)
66/72 Total tumors+ NP NP Poltermann
et al.
2006
HHV-4
(EBV)
GBM(N=48) other brain tumor
subtypes (N=69)
41/48 GBM+, 62/69 other brain
Ttumor subtypes+, 139/151 non-
brain tumor control+
NP NP Wrensch et
al. 2001
GBM (N=115), other brain
tumor subtypes (N=113)
106/115 GBM+, 105/113 other
brain tumor subtypes+, 266/283
non-brain tumor control +
NP NP Wrensch et
al. 2005
Pilocytic astrocytoma (N=35) NP 9/35 Pilocytic Astrocytoma +, 7/9
Non-Tumor Control+ by qPCR
NP Neves et
al. 2008
Glial tumors (N=35),
meningiomas (N=31)
acoustic schwanommas
(N=6)
64/72 Total tumors+ NP NP Poltermann
et al.
2006
HHV-5
(CMV)
GBM, anaplastic astrocytoma,
diffuse fibrillary astrocytoma,
meningioma
NP 7/9GBM+ (nPCR);12/12 GBM
+,4/4 diffuse fibrillary
astrocytoma+, 0/5 meningioma
+,0/8 normal brain, 0/9 other
neurological diseases (ISH)
38/38 GBM+, 1/1 anaplastic
astrocytoma, 6/6 diffuse fibrillary
astrocytoma+, 0/9 meningioma+,0/6
normal brain, 0/9 other neurological
diseases (IHC using 3 antibodies)
Cobbs et
al. 2002
GBM, primary GBM cell
culture
Peripheral
blood
samples
NP 29/68 GBM+, 22/34 primary GBM
cell culture+ (nPCR with 2
primers);16/16 GBM+ (ISH);16/
20 peripheral blood+ , 0/17 non-
tumor controls+ (PCR)
72/78 GBM+, 16/16 primary
GBM cell cultures+ ( IHC using
two antibodies)
Mitchell et
al. 2008
GBM (N=21), anaplastic
astrocytoma (N=12), low-
grade glioma (N=17)
NP NP 21/21GBM+,9/12 anaplastic
astrocytoma+,14/17 low-grade glioma
+,0/6 non-brain tumor controls+
(IHC)
Scheurer et
al. 2008
Glial tumors (N=35),
meningiomas (N=31)
acoustic schwanommas
(N=6)
46/72 Total Tumors+ 0/72 Total tumors+ (nPCR with
two primers)
0/72 Total tumors+ (IHC using 2
antibodies)
Poltermann
et al.
2006
GBM (N=8), diffuse fibrillary
astrocytoma (N=3),
anaplastic astrocytoma (N=
6), oligodendrioglioma (N=
2), ependymoma (N=3)
NP 0/22 Total tumors+, 0/4 normal
brain+, 0/24 other neurological
diseases+ (nPCR, ISH)
0/22 Total tumors+, 0/4 normal brain+,
0/24 other neurological diseases+
(IHC)
Lau et al.
2005
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EBV, a member of the gamma herpesvirus family, is present
in greater than 90% of the population and is characterized
by its persistence largely in lymphocytes (Volpi 2004).
EBV has been detected in greater than 95% of primary
CNS lymphoma in HIV-related disease and 5% of CNS
lymphoma in immunocompetent hosts (Gulley 2001).
Seropositivity for EBV is high in sera of patients with
GBM (85–92%), other CNS tumor subtypes (90–93%), and
non-tumor control sera (92–94%; Wrensch et al. 2001;
Wrensch et al. 2005; Poltermann et al. 2006). Interestingly,
Neves et al. reported 9/35 EBV-positive pilocytic astrocy-
tomas by quantitative PCR (their highest for any herpesvi-
rus tested), however seven of nine normal cerebellum were
also were positive by PCR (Neves et al. 2008; Table 1).
Like HSV-1/2, there are no published reports on the
frequency of EBV viral antigens in non-CNS lymphoma
tumors by IHC.
Human cytomegalovirus
Human cytomegalovirus (CMV), a member of the betaher-
pesvirus family, has been the most studied and perhaps the
Table 1 (continued)
Herpesvirus
subtype
Tumor histology subtypes Serum viral IgG antibody detection
(ELISA)
Viral nucleic acid detection (PCR,
nPCR, qPCR, ISH)
Viral protein detection (IHC) Reference
GBM (N=97), ependymoma
(N=15), oligodendroglioma
(N=20)
NP 7/97 GBM+, 0/15 ependymoma+,
0/20 oligodendroglioma+ (ISH)
9/97 GBM+ ,0/15 ependymoma+, 0/20
oligodendroglioma+ (ISH)
Sabatier et
al. 2005
GBM (N=37) other brain tumor
subtypes (N=39)
24/37 GBM+, 20/39 other brain
tumor subtypes+, 54/94 non-
brain tumor control+
NP NP Wrensch et
al. 2001
GBM (N=115), other brain
tumor subtypes (N=113)
71/115 GBM+, 61/113 other brain
tumor subtypes+, 163/287 non-
brain tumor control +
NP NP Wrensch et
al. 2005
HHV-6 Extensive series of glial and
neuronal Tumors (N=98)
NP 4/36 Meningioma+,1/18 GBM+,
3/5 ependymoma+ (nPCR)
Chan et al.
1999
Glial and neuronal tumor
subtypes (N=37)
NP 6/37 Total tumors+ (nPCR) NP Luppi et al.
1995
Extensive series of glial and
neuronal tumors (N=118)
90/115 Total tumors+, 106/150
non-tumor controls+
14/31 GBM+, 2/2 neuroblastoma
+, 9/35 meningioma+, 1/2
ependymoma+, 2/6 astrocytoma
+, 15/39 other brain tumor
subtypes+ (nPCR)
4/10 Tumors+ (IHC) Cuomo et
al. 2001
Pediatric pilocytic astrocytoma
(N=35)
NP 0/35 Pilocytic astrocytoma+, 0/10
non-tumor control+ by qPCR
NP Neves et
al. 2008
Extensive series of pediatric
glial and neuronal tumors
(N=150)
NP 141/240 Total tumors+, 18/64
non-brain tumor controls+
(nPCR with two primers); 83/
150 total tumors+, 10/32 non-
brain tumor controls+ (ISH)
50/124 Total tumors+, 6/32 non-brain
tumor controls+ (IHC)
Crawford
et al.
2009a
Extensive series of pediatric
glial and neuronal tumors
(N=282)
NP 14/30 Total tumors+, 0/25 non-
tumor controls+ (nPCR); 106/
224 total tumors+, 0/25 non-
tumor controls+ (ISH)
150/559 Total tumors+, 0/25 non-tumor
controls+ (IHC with two antibodies)
Crawford
et al.
2009b
GBM (N=23), anaplastic
astrocytoma (N=3),
anaplastic oligodendroglioma
(N=2), medulloblastoma
(N=12)
NP 0/41 Total tumors+ (by digital
karyotyping)
NP Duncan et
al. 2009
HHV-7 Extensive series of glial and
neuronal tumors (N=98)
NP 5/36 Meningioma+, 3/18 GBM+,
1/5 ependymoma+, 1/
8 schwannoma+, 2/16 other
astrocytoma+, 2/5 other brain
tumors+ (nPCR)
Chan et al.
1999
Pediatric pilocytic astrocytoma
(N=35)
NP 1/35 Pilocytic astrocytoma+, 0/6
non-tumor control+ by qPCR
NP Neves et
al. 2008
HHV-8
(KSV)
Pediatric pilocytic astrocytoma
(N=35)
NP 0/35 Pilocytic astrocytoma+, 0/6
non-tumor control+ by qPCR
NP Neves et
al. 2008
Abbreviations: NP not performed, ELISA enzyme-linked immunosorbent assay, PCR polymerase chain reaction, nPCR nested polymerase chain
reaction, qPCR real-time quantitative polymerase chain reaction, ISH in situ hybridization, IHC immunohistochemistry, GBM glioblastoma
multiforme
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primary CNS tumors (Miller 2009). In terms of CMV IgG
seropositivity in patients with primary CNS tumors, there
has been a slight non-significant increase in positivity
among patients with GBM (62–66%) compared to sera
from other CNS malignancies (51–54%) or non-tumor
control sera (57%) (Wrensch et al. 2001; 2005). Much of
the published data in support of a role for CMV in CNS
tumorigenesis comes from the detection of viral nucleic
acids by PCR and ISH and proteins by IHC (Table 1).
Cobbs et al. first reported a strong association between
CMV and GBM (Cobbs et al. 2002). Using nested PCR
with primers for the UL55 glycoprotein B gene, they
reported positivity in 7/9 GBMs. ISH was used to confirm
PCR findings with both whole-genome CMV primers (4/4
GBM, 2/2 diffuse fibrillary astrocytoma) and immediate
early gene CMV primers (8/8 GBM, 2/2 diffuse fibrillary
astrocytoma). CMV was not detected in normal control
brain by PCR or ISH in this study (Cobbs et al. 2002). The
strong association of CMV and GBM was further
demonstrated by IHC using IEI-72 immediate early
antibody (22/22), p52/76 immediate early/early antigen
antibody (8/8), and pp65 tegument protein antibody (8/8;
Cobbs et al. 2002). Similar IHC results were observed in
other glial tumor subtypes (6/6 diffuse fibrillary astrocy-
toma, 1/1 anaplastic astrocytoma), but not in non-glial
tumors (0/9 meningioma), non-tumor brain (0/6), or brain
from other neurological diseases (0/9; Cobbs et al. 2002).
On the contrary, Sabatier et al. reported that less than 10%
of GBMs in their French series were positive for CMV by
either ISH (7/97) or IHC (9/97; Sabatier et al. 2005). This
study was followed by two other studies that failed to
detect CMV in a series of 22 (Lau et al. 2005)o r7 2
(Poltermann et al. 2006) GBMs by PCR, ISH, or IHC
using two different antibodies. More recently, two groups
have reported widespread detection of CMV in GBM
using similar techniques described by Cobbs et al.
(Mitchell et al. 2008;S c h e u r e re ta l .2008). Scheurer et
al. reported strong positivity for CMV by IHC in GBM
(21/21), anaplastic astrocytoma (9/12), and low-grade
astrocytoma (14/17) compared with non-tumor brain
controls (0/6; Scheurer et al. 2008). Mitchell et al.
r e p o r t e ds t r o n gp o s i t i v i t yo fG B M sb yn e s t e dP C R( 2 9 /
68), ISH (16/16), and IHC (72/78) compared with non-
tumor controls. Additionally, Mitchell et al. reported
similar finding in short-term primary glioblastoma cul-
tures (23/34 PCR+, 16/16 IHC+) and in peripheral blood
of patients with GBM (16/20) compared with controls
(Mitchell et al. 2008). It has been suggested that tissue
processing, amount of template DNA used for PCR, and
concentrations and conditions of IHC methodology may
all be possible explanations for discrepancies among
researchers (Scheurer et al. 2007).
Human Herpesvirus-6
Human herpesvirus-6 (HHV-6) is a member of the
betaherpesvirus and exists as two variants A (HHV6-A)
and B (HHV6-B; Caserta 2004; De Bolle et al. 2005).
HHV-6 B is the causative agent of the common viral
exanthematous disease roseola infantum (Yamanishi et al.
1988), while HHV-6 A has been shown to have more
neurotropic features (Hall et al. 1998), including altering
cytokine synthesis in astrocyte cell lines (Yoshikawa et al.
2002). Initially discovered as a B cell lymphotropic virus,
chromosomally integrated forms of HHV-6 have been
recognized and may play a role in disease pathogenesis
(Clark and Ward 2008; Hall et al. 2008). In terms of HHV-6
seroprevalence, greater than 90% of humans become
seropositive within the first year of life (Okuno et al.
1989; Hall et al. 1994; Zerr et al. 2005). Regarding primary
CNS tumors, one study revealed significant differences in
seroreactivity measured by indirect immunofluorescence in
brain tumor patients (90/115) versus controls (106/150)
(Cuomo et al. 2001). The same study reported HHV-6 PCR
positivity in 45% of GBMs (14/31) and 4/10 tumors
expressed early HHV-6 viral antigen p41 detected by IHC
(Table 1). Others have reported between 14–16% of brain
tumor samples were positive by nested PCR (Luppi et al.
1995; Chan et al. 1999). Most recently, we reported the
detection of HHV-6 in a large series of previously untreated
fresh frozen and paraffin-embedded pediatric primary CNS
brain tumors by nested PCR, ISH, and IHC (Crawford et al.
2009a). HHV-6 variants were detected in tumors by nested
PCR (59%), ISH (55%), and IHC (40%), significantly
more than age-matched non-tumor brain. Interestingly, the
low-grade gliomas showed significantly higher immunopo-
sitivity for the HHV-6 glycoprotein gp116/64/54 than
higher-grade glial and non-glial tumor subtypes. We
reported similar frequencies of HHV-6 positivity by nested
PCR (47%), ISH (47%), and ICH (27%) in a large adult
cohort of paraffin-embedded brain tumors (Crawford et al.
2009b). In both studies, the glial tumors were significantly
more positive by IHC than non-glial tumors, and there was
a predominance of HHV6-A confirmed by sequence
analysis. The major differences between the adult and
pediatric studies include the lack of association between
tumor grade and IHC positivity in adults and the lack of
detection of virus in a small number of adult non-tumor
brain (Crawford et al. 2009ab). Contrary to our findings,
Neves et al. reported no detectable HHV-6 in a series of
non-paraffin-embedded normal cerebellum and pilocytic
astrocytomas by quantitative PCR (Neves et al. 2008).
Since few of our samples were primary PCR-positive for
HHV-6, it is likely that CNS tumors harbor virus at very low
levels. Although the concept of a neurotropic viral infection
obtained during early childhood as a potential modifier in
J Neuroimmune Pharmacol (2010) 5:387–403 391CNS neuro-oncogenesis is tempting, more work still needs to
be done to determine what role, if any, HHV-6 plays in
primary CNS brain tumors.
Human herpesvirus-7 and human herpesvirus-8
Human herpesvirus-7 (HHV-7) and human herpesvirus-
8 (HHV-8) are relatively newly described herpesviruses
with little published findings with regard to CNS malig-
nancy. No seroprevalence data in conjunction with CNS
tumors has been published to date on either virus. HHV-7
has been detected by PCR in 3% (1/35) to 16% (14/88) of
CNS tumors (Chan et al. 1999; Neves et al. 2008; Table 1).
HHV-8 was not detected by PCR in a series of 35 pediatric
pilocytic astrocytomas (Neves et al. 2008). More wide-
spread serological and biological studies are necessary to
determine whether HHV-7 and HHV-8 play a role in CNS
brain tumors.
Detection of polyomaviruses in primary CNS
malignancies
JC virus
The JCV was first discovered in 1971, isolated from the
brain of a patient with progressive multifocal leukoence-
phalopathy, a degenerative, demyelinating disease (Padgett
et al. 1971). Since then, the JCV has been found
experimentally to be oncogenic in both animal models
and human-derived cell lines (extensively reviewed in
Croul et al. 2003; White et al. 2005; Barbanti-Brodano et
al. 2006; Maginnis and Atwood 2009; Ahsan and Shah
2006; Jiang et al. 2009). The seroprevalence of JCV in the
human population is estimated to range from around 19–
50% and increases with age (Knowles et al. 2003).
A summary of the experimental approaches used in
detection of JCV in human primary CNS tumors is
summarized in Table 2. Researchers have largely employed
PCR and Southern blot hybridization techniques for
sensitive detection of JCV genome and IHC for the viral
proteins. In the case of JCV, IHC has been used to detect
both large T antigen (TAg) and agnoprotein, both involved
in JCV oncogenesis. As summarized in Table 2, JCV has
been detected in a wide variety of diverse CNS tumor
subtypes. Of all studies which report JCV positivity by
PCR, only oligodendroglioma (13/18), astrocytoma (14/
26), ependymoma (5/18), GBM (19/34), and medulloblas-
toma (22/39) were studied in sufficient quantity to have
significance. Of all the studies, only four were done in
pediatric CNS tumors (Boldorini et al. 1998; Krynska et al.
1999; Okamoto et al. 2005; Vasishta et al. 2009). The
percentage of JCV IHC positivity is roughly half of that
reported by PCR for each tumor subtype across the majority
of both pediatric and adult studies employing both technol-
ogies. In the case of medulloblastoma, several researchers
have failed to detect JCV by both PCR and IHC (Hayashi et
al. 2001; Kim et al. 2002; Okamoto et al. 2005; Vasishta et
al. 2009). The differences between the groups is not entirely
clear and may be related to the sensitivities of the PCR
methodologies used, as JCV DNA fragments (and not viral
antigens) have been recently reported in a small series of
normal human brain (Perez-Liz et al. 2008).
BK virus
First discovered in 1971, the BK virus was originally found
in the urine of a renal transplant patient with renal stenosis
(Gardner et al. 1971). Similar to JCV, BKV’s oncogenicity
in experimental animal models and association with human
disease, namely hemorrhagic cystitis and polyomavirus
nephropathy, has been well-studied and reviewed (Tognon
et al. 2003; Fioriti et al. 2005; Yogo et al. 2009; Abend et
al. 2009; Jiang et al. 2009). Opposite to JCV, BKV
seroprevalence reaches around 90% in children 5 to 9 years
and decreases in prevalence with advanced age (Knowles et
al. 2003).
As was the case with JCV, BK virus has been detected in
a wide variety of primary CNS tumor subtypes as shown in
Table 2. BK virus has been detected in highest numbers by
PCR in astrocytoma (16/17), ependymoma (10/11), and
GBM (28/30) (Martini et al. 1996), while none has been
detected in medulloblastoma (0/15; Kim et al. 2002). On
the contrary, Arthur et al. were unable to detect BK virus in
any of the 75 tumors tested by PCR (Arthur et al. 1994).
IHC has not been performed on a large subset of CNS
tumors, however, BK virus TAg has been reported in 8/10
glial tumors by RT-PCR (Martini et al. 1996).
SV40 Virus
The SV40 was first introduced into the human population
through preparations of contaminated polio vaccines
administered between the years 1955 and 1963. The natural
host of SV40 is the rhesus macaque, and its horizontal
transmission among humans as well as its causative role in
human disease has come under question (Butel et al. 1997;
Jasani et al. 2001; Klein et al. 2002; Gazdar et al. 2002;
Carbone et al. 2003; Garcea 2001; Garcea and Imperiale
2003; Ahsan and Shah 2006;a n dP i p a s2009). The
seroprevalence of SV40 is estimated to range from 1.3%
to 5% in groups of all ages (Knowles et al. 2003). As
shown in Table 2, the overall percentage of tumors positive
for SV40 by PCR is lower than reported for the other
polyomaviruses. The lower-grade tumors (choroid plexus
papilloma, astrocytoma, meningioma, ependymoma) tended
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Detected/sampled (%) Detection method
DNA Proteins DNA Proteins Reference
JC virus
Gangliocytoma 0/1 0/1 nPCR, PCR IHC (TAg) Boldorini et al. 2003
Choroid plexus papilloma 1/5 (20) 1/5 (20) PCR, SB IHC (TAg, Agno) Okamoto et al. 2005
Pilocytic astrocytoma 4/5 (80) 1/5 (20) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
0/7 0/7 PCR, SB IHC (TAg, Agno) Okamoto et al. 2005
Subependymoma 1/1 (100) 1/1 (100) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
Pleomorphic xanthoastrocytoma 1/1 (100) – nPCR IHC (TAg) Boldorini et al. 1998
Oligodendroglioma 4/7 (57) – PCR, SB IHC (TAg) Del Valle et al. 2001a, b
13/18 (72) 8/18 (44), 10/18 (56) PCR, SB IHC (TAg, Agno) Del Valle et al. 2002a
1/2 (50) 1/2 (50) nPCR, PCR IHC (TAg) Boldorini et al. 2003
1/5 (20) 0/5 nPCR IHC (TAg) Caldarelli-Stefano et al. 2000
Astrocytoma (all subtypes) 4/10 (40) 1/10 (10) nPCR IHC (TAg) Caldarelli-Stefano et al. 2000
1/3 (33) 1/3 (33) nPCR, PCR IHC (TAg) Boldorini et al. 2003
10/16 (63) 7/16 (44) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
Ependyoma 5/6 (83) 4/6 (67) PCR, SB IHC (TAg) Del Valle et al. 2001a
5/18 (28) 4/18 (22), 3/18 (17) PCR, SB IHC (TAg, Agno) Okamoto et al. 2005
0/2 0/2 nPCR, PCR IHC (TAg) Boldorini et al. 2003
1/5 (20) 0/5 nPCR IHC (TAg) Caldarelli-Stefano et al. 2000
Oligoastrocytoma 5/8 (63) 2/8 (25) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
1/1 (100) 1/1 (100) PCR IPPt (TAg) Rencic et al. 1996
Anaplastic oligodendroglioma 2/3 (67) 2/3 (67) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
Anaplastic astrocytoma 3/4 (75) 0/4 PCR, SB IHC (TAg) Del Valle et al. 2001a, b
Anaplastic oligodendroglioma 2/3 (67) 2/3 (67) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
2/2 (100) 2/2 (100), 1/2 (50) PCR, SB IHC (TAg, Agno) Del Valle et al. 2002a
Gliomatosis cerebri 1/1 (100) 1/1 (100) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
GBM 12/21 (57) 5/21 (24) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
1/1 (100) 1/1 (100) PCR, SB IHC (TAg) Del Valle et al. 2000
7/13 (54) 7/13 (54) nPCR, PCR IHC (TAg) Boldorini et al. 2003
1/1 (100) 1/1 (100), 1/1 (100) PCR IHC (TAg, Agno) Pina-Oviedo et al. 2006
Medulloblastoma 11/16 (68) 9/16 (56), 11/16 (68) PCR IHC (TAg, Agno) Del Valle et al. 2002b
0/8 0/8 PCR, SB IHC (TAg) Hayashi et al. 2001
11/23 (48) 4/23 (17) PCR, SB IHC (TAg) Krynska et al. 1999
0/15 0/15 PCR, SB IHC (TAg) Kim et al. 2002
– 0/22 – IHC (TAg, Agno) Vasishta et al. 2009
0/32 0/32 PCR, SB IHC (TAg) Okamoto et al. 2005
Pineoblastoma 0/1 0/1 nPCR, PCR IHC (TAg) Boldorini et al. 2003
Gliosarcoma 1/1 (100) 1/1 (100) PCR, SB IHC (TAg) Del Valle et al. 2001a, b
sPNET 0/5 0/5 PCR, SB IHC (TAg) Kim et al. 2002
BK virus
Choroid plexus papilloma 6/6 (100) – PCR, SB Martini et al. 1996
Oligodendroglioma 1/1 (100) – SB Dorries et al. 1987
7/9 (78) – PCR, SB Martini et al. 1996
Astrocytoma 0/3 – SB Dorries et al. 1987
16/17 (94) 1/1 (100) PCR, SB RT-PCR (TAg) Martini et al. 1996
Ependymoma 10/11 (91) – PCR, SB Martini et al. 1996
2/3 (60) – PCR, SB Negrini et al. 1990
Medulloblastoma 0/15 0/15 PCR, SB IHC (TAg) Kim et al. 2002
GBM 0/75 – PCR Arthur et al. 1994
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Detected/sampled (%) Detection method
2/5 (40) – SB Dorries et al. 1987
28/30 (93) 7/9 (78) PCR, SB RT-PCR (TAg) Martini et al. 1996
Brain tumor (mixed subtypes) 19/74 (26) – SB Corallini et al. 1987
50/58 (86) – PCR, SB De Mattei et al. 1995
Meningioma 5/6 (83) – SB Dorries et al. 1987
4/7 (57) – PCR, SB Martini et al. 1996
Neurinoma 3/3 (100) – SB Dorries et al. 1987
sPNET 0/5 0/5 PCR, SB IHC (TAg) Kim et al. 2002
Simian virus 40
Choroid plexus papilloma 5/6 (83) – PCR, SB Martini et al. 1996
10/20 (50) – PCR, IHC (TAg) Bergsagel et al. 1992
6/16 (38) – PCR, SB Huang et al. 1999
– 1/39 (3) IHC (TAg) Tabuchi et al. 1978a, b
10/13 (77) – PCR Lednicky et al. 1995
1/14 (7.1) 0/7 PCR RT-PCR Engels et al. 2002
Subependymoma 1/2 (50) – PCR Weggen et al. 2000
Oligodendroglioma 3/12 (25) – PCR, SB Huang et al. 1999
0/9 – PCR, SB Martini et al. 1996
1/3 (33) – SB Krieg et al. 1981
Astrocytoma (all subtypes) 8/17 (47) – PCR, SB Martini et al. 1996
0/3 – SB Krieg et al. 1981
22/50 (44) – PCR, SB Huang et al. 1999
1/8 (13) – SB Krieg et al. 1981
Ependymoma 10/11 (9) – PCR, IHC (TAg) Bergsagel et al. 1992
– 1/39 (2.6) IHC (TAg) Tabuchi et al., 1978a, b
3/3 (100) – PCR Lednicky et al. 1995
8/11 (73) – PCR, SB Martini et al. 1996
0/33 – PCR RT-PCR Engels et al. 2002
Anaplastic ependymoma 1/25 (1) – PCR Weggen et al. 2000
Anaplastic meningioma 1/131 (1) 0/131 PCR IHC (TAg) Weggen et al. 2000
GBM 10/30 (33) – PCR, SB Martini et al. 1996
0/3 – SB Krieg et al. 1981
1/7 (14) – D-DH Meinke et al. 1979
3/13 (23) – PCR IHC (TAg) Kouhata et al. 2001
Medulloblastoma 2/6 (33) 0/13 PCR Lednicky et al. 1995
5/17 (29) – PCR, SB Huang et al. 1999
2/116 (2) 0/116 PCR IHC (TAg) Weggen et al. 2000
0/15 0/15 PCR, SB IHC (TAg) Kim et al. 2002
1/2 (50) – SB Krieg et al. 1981
Meningioma 1/7 (14) – PCR, SB Martini et al. 1996
5/16 (31) – SB Krieg et al. 1981
sPNET 0/5 0/5 PCR, SB IHC (TAg) Kim et al. 2002
Abbreviations used: PCR polymerase chain reaction, RT-PCR real-time PCR, nPCR nested PCR, IHC immunohistochemistry, SB Southern blot,
IPPt immunoprecipitation, D-DH DNA-DNA rehybridization kinetics, TAg T antigen, Agno agnoprotien, GBM glioblastoma multiforme, sPNET
supratentorial primary neuroectodermal tumor
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anaplastic ependymoma, medulloblastoma, supratentorial
PNET) with little known about T antigen expression by
IHC. As with the other polyomaviruses, some groups have
failed to detect SV40 DNA by PCR in ependymoma (0/30;
Engels et al. 2002) and medulloblastoma (Kim et al. 2002),
while Weggen et al. reported minimal detection of SV40 in
meningioma (1/131) and medulloblastoma (2/116; Weggen
et al. 2000).
Detection of adenovirus in primary CNS malignancies
Adenovirus is a human DNA virus that currently includes
51 serotypes and six species (Benko 2000; Shenk and
Horwitz 2001) and has been shown to induce multiple
tumors in newborn hamsters including neuroectodermal
tumors and medulloblastoma (Yabe et al. 1962; Hohlweg et
al. 2004). Kosulin et al. recently screened a series of 538
solid tumors and leukemias/lymphomas for the presence of
adenovirus subtypes by real-time PCR and ISH (Kosulin et
al. 2007). Adenovirus species were detected by PCR in
ependymoma (20/30, species B,D,C), GBM (25/30, species
B,D), and oligoastrocytoma (22/30, species B), while none
were reported positive in astrocytoma, medulloblastoma, or
germinoma. A subset of PCR-positive and PCR-negative
samples were confirmed by ISH using adenovirus-specific
probes. Among the adenoviral oncogenes detected in this
study were E1A, EIB, and E4 ORF-1, the products or
which have been shown to exhibit transforming capacity in
animal models (White and Cipriani 1990; Shenk and Flint
1991; Javier 1994). A specific role, if any, of adenovirus
infection in primary CNS tumors remains unclear since in
the same study the authors report 11/20 normal brain harbor
adenovirus DNA sequences (Kosulin et al. 2007).
Molecular mechanisms of viral-mediated CNS
neuro-oncomodulation
Alpha herpesviruses
While few studies have been performed to investigate the
prevalence of the alpha herpesviruses (HSV-1/2, VZV) in
primary CNS tumors, aside from serological studies, this
family of herpesviruses has been shown to interact with and
regulate the retinoblastoma (Rb) tumor suppressor pathway;
awell-characterizedpathwayinvolvedoncogenesis(Hayward
et al. 2006; Hume and Kalejta 2009). As illustrated in Fig. 1,
Rb is a transcriptional co-repressor (along with p107, p130)
that regulates cellular proliferation and differentiation.
During cellular senescence, the active hyperphosphorylated
form of Rb binds to transcription factor E2F to repress
transcriptional activity. In HSV-infected cells, Rb is held
in its inactive hypophosphorylated state, possibly due to
low cyclin-dependent kinase (CdK) activity. HSV-1, in
particular, prevents Rb phosphorylation and through
mislocalization, keeps CdK inactive. In the case of
VZV, Rb and p107 remain unphosphorylated, in spite
of normal CdK activity. One report demonstrated that
HSV-2-infected cells induced Rb phosphorylation (Hossain
et al. 1997). However, since many of the in vitro studies of
HSV-induced hypophosphorylation of Rb was performed in
cycling cells, little is known about the effects of latent
infection on cellular growth and differentiation in either CNS
tumor cell lines or actual disease.
Beta herpesviruses (CMV, HHV-6, and HHV-7)
CMV is perhaps the most well-studied of the herpesviruses
with regards to potential molecular mechanisms of neuro-
oncogenesis. In particular, the term oncomodulation has
been coined to describe how this virus could infect a
tumor cell and increase its already malignant potential
(Cinatl et al. 1996; Cinatl et al. 2004ab; Michaelis et al.
2009). With regard to oncomodulation in the CNS or neuro-
oncomodulation, CMV infection has been shown to modify
key molecular oncologic pathways including apoptosis, cell
migration, angiogenesis, telomerase activity, and Rb tumor
suppressor modulation (Michaelis et al. 2009) as outlined in
Fig. 1. In contrast to the alphaherpesviruses, CMV induces
a hyperphosphorylation of Rb following infection of
senescent cells (Jault et al. 1995) by activating cyclin E
and cyclin-B-dependent kinases. As a consequence of the
hyperphosphorylation of Rb, E2F response genes are highly
expressed, perhaps due to interaction with CMV immediate
early protein 2 (Song and Stinski 2002).
In terms of apoptosis, CMV infection has been shown to
prevent death in cancer cells (Michealis et al. Michaelis et al.
2004) through expression of numerous anti-apoptotic pro-
teins (Goldmacher 2005). The CMV UL36 has been shown
to inhibit Fas-mediated apoptosis via caspase 8 binding
(Skaletskaya et al. 2001). CMV UL123/124 proteins have
been shown to inhibit apoptosis by activating the PI3 kinase
activity (Yu and Alwine 2002). CMV UL37 inhibits
apoptosis by disrupting mitochondrial networks through an
uncharacterized mechanism (McCormick et al. 2003). In
addition to apoptotic mechanisms, CMV infection has been
s h o w nt oi n c r e a s es m o o t hm u s c l ec e l lm i g r a t i o n ,p e r h a p s
by beta-1 alpha-5 integrin-mediated binding to endothe-
lin (Scholz et al. 2000) or in the case of glial cells, by an
increase in AKT kinase activity (Cobbs et al. 2007, 2008).
CMV may also promote oncogenesis by increasing
telomerase activity, since human diploid cells and malignant
cells infected with CMV show increased telomerase activity
by stimulating hTERT gene expression (Straat et al. 2009).
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show downregulation of many negative regulators of angio-
genesis including thrombospondin 1 and 2 (Cinatl et al. 1999,
2000). Tumor necrosis alpha, a proinflammatory cytokine
known to stimulate angiogenic factors in gliomas (VEGF,
IL8; Nabors et al. 2003), has also been reportedly increased
following CMV infection of GBM cell lines (Baillie et al.
2003). Additionally, CMV has been shown to induce CD40
expression on the surface of infected cells, which, upon
binding to CD40 ligand, results in increased VEGF
production (Maisch et al. 2002). More recently, CMV has
been shown to interact with the epidermal growth factor
receptor (Wang et al. 2003) and platelet-derived growth
factor receptor alpha (Soroceanu et al. 2008), two members
of the receptor tyrosine kinase (RTK) family of receptors
known to be upregulated in a number of primary CNS
malignancies. While there is still some debate about the
exact putative receptor of CMV-mediated entry and patho-
genesis, modulation of either or both of the RTK pathways
would help to support a role of CMV in neurooncogenesis.
An indirect role for HCMV in neuro-oncomodulation is also
possible, as HCMV has been shown to activate critical cell
proliferative pathways in the absence of viral gene expres-
sion (Shibutani et al. 1997, Boyle et al. 1999, Johnson et al.
2000, 2001a, b).
Potential neuro-oncomodulatory mechanisms of chronic
HHV-6 and HHV-7 infected CNS-derived cells are much
less well-understood. Since HHV-6 has been shown to be
chromosomally integrated in a subset of the population
detected at birth (Hall et al. 2008), the role of chronic
persistent infection on cellular proliferative mechanisms is
not clear. One potential candidate is the HHV-6 viral
oncogene that has been detected in human GBM by PCR
and directly interacts with P53 (Kashanchi et al. 1997).
Fig. 1 Molecular mechanisms of CNS neuro-oncomodulation. The
known proliferative molecular mechanisms of herpesvirus and poly-
omavirus infections on promoting gene expression, inhibition of
apoptosis, and enhancing cell motility are shown (black arrows). In
general, five major signaling pathways converge to promote onco-
genesis for both families of viruses (green arrows), namely NOTCH/
WNT, receptor tyrosine kinase RTK (EGFR/PDGFR), telomerase
(Tel), retinoblastoma protein-E2F, and P53 pathways as described in
the text
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Although the gammaherpesviral infections have been
reported predominantly in B cells, both EBVand HHV-8 are
oncogenic viruses which directly interact with elements of
two key regulatory pathways in neuro-oncogenesis, namely
Notch and WNT (Fig. 1; Hayward et al. 2006). The Notch
pathway is composed of a subfamily of receptors (Notch1-4)
and ligands (Jagged1,2, Delta-like 1,3,4,), that upon binding
of ligand to receptor results in cleavage of the intracellular
Notch receptor domain (Notch IC). Notch IC then binds to
CSL, a DNA binding protein and nuclear effector of the
Notch pathway, displacing it and thus promoting transcrip-
tion. EBV protein EBNA2 specifically interacts with CSL
stimulating cellular proliferation and is necessary for the
establishment of viral latency (Hayward et al. 2006). Similar
to EBV, HHV-8 also interacts with CSL, but this interaction
is critical for lytic infection as opposed to latency.
The WNT pathway is a complex pathway involving cell
surface receptors, cytosolic complexes, and nuclear effectors,
all designed to regulate cellular proliferation and differenti-
ation. The WNT family of glycoproteins binds to the frizzled
family of receptors and co-receptors (Lrp5/8) that ultimately
results in the regulation of beta catenin, the nuclear effector
of the WNT pathway, whose expression has been positively
associated with a favorable prognosis in a number of CNS
malignancies (Ellison et al. 2005;R o g e r se ta l .2009). The
availability of nuclear beta catenin is dependent on the
regulation of its phosphorylation by an extensive complex
composed in part by APC, CKI, and GSK-3 (Fig. 1). In the
phosphorylated state (promoted by both CKI and GSK-3),
beta catenin is targeted for intracytosolic destruction by
proteosome degradation. In the active non-phosphorylated
state, beta catenin is responsible for the transcription of
numerous neuroonco-proliferative genes including C-myc,
N-myc, cyclin C1, MMP-7, VEGF, surviving, axin 2, and c-
Jun, among others (Hayward 2004). HHV-8 infection results
in high cytoplasmic levels of beta catenin, due to its
interaction with the HHV-8 latency-associated nuclear
antigen (LANA). LANA causes dysregulation of beta
catenin by inducing a nuclear translocation of GSK-3,
essentially saving beta catenin from degradation. EBV
similarly stabilizes beta catenin, through interactions with
the EBV protein LMP-1, via unknown mechanisms.
The gammaherpesviruses also have regulatory interactions
with the Rb pathway as per the other herpesviruses. EBV
encodes many proteins (Z,R,LMP-1,EBNA-2,3C,S) that can
lead to Rb phosphorylation by activation of cellular Cdk’so r
through direct phosphorylation by viral encoded kinases
(Hayward et al. 2006, 2004). HHV-8 can similarly activate
the Rb pathway by disruption of Rb–E2F interactions
mediated by LANA, v cyclin or HHV-8 ORF36-encoded
proteins (Rajcani and Kudelova 2003; Hamza et al. 2004).
Polyomaviruses (BKV, JCV, and SV40)
Each of the polyomaviruses share similar oncogenic
mechanisms via interactions between the two viral T
antigens (small T-tAG, large T-TAG) and key cellular
regulatory pathways such as P53 and Rb as illustrated in
Fig. 1 (Croul et al. 2003; Barbanti-Brodano et al. 2006; Lee
and Langhoff 2006). The large TAG is the major oncogenic
antigen and acts by directly increasing cell proliferation,
inhibiting apoptosis, and damaging DNA. TAG has been
shown to bind to unphosphorylated Rb, causing release of
E2F and subsequent cell cycle progression. Alternatively,
TAG can modify Rb degradation pathways through binding
of molecular chaperone protein hsp70 (Lee and Langhoff
2006). TAG has been shown to bind to P53 tumor
suppressor protein, resulting in uncontrolled cellular proli-
feration and blockage of apoptosis (Harris et al. 1996). This
may work through inhibition of p21/WAG-1, a stabilizing
complex upstream of cyclin dependent kinase-cdK. Alter-
natively, TAG can also affect P53-mediated transcription
without directly binding to P53 (Rushton et al 1997).
Lastly, TAG can promote oncogenesis by causing direct
chromosomal damage in cultured human cells infected with
BK and SV40 viruses (Ray et al. 1990; Stewart and
Bacchetti 1991; Trabanelli et al. 1998), or by interfering
with topoisomerase I and helicase activities (Simmons et al.
1996; Dean et al. 1987).
Polyomavirus small t antigen (tAG) promotes cell
division through interaction with PP2A and phosphatidyli-
nositol 3-kinase regulatory pathways (Barbanti-Brodano et
al. 2006; Fig. 1). tAG has been shown to inhibit PP2A
function, a major regulator of the WNT/beta catenin
pathway, by directly binding to both regulatory and
catalytic PP2A domains (Garcea and Imperiale 2003;
Barbanti-Bordano et al. 2004, 2006). As a consequence,
the WNT pathway is inhibited and beta catenin is free to
translocate to the nucleus to stimulate gene expression. In
addition, PP2A inactivation by tAG affects cytoskeletal
integrity and promotes tumor migration in epithelial cells
(Nunbhakdi-Craig et al. 2003) infected with SV40 virus.
Discussion
The concept of viral-associated CNS malignancy has been
met with appropriate skepticism from the scientific com-
munity. The major difficulties in establishing a more
widespread acceptance of the concept of viral-mediated
CNS disease are due in part to: lack of reproducible
findings among researchers regarding viral detection in
CNS tumors, paucity of animal model systems to study
direct viral mechanisms of neuro-oncogenesis, high sero-
prevalence among controls and tumors alike, lack of stable
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tumors, and inability to induce transformation in non-
cancerous primary human CNS-derived cell lines.
Among potential possibilities to explain discrepancies of
viral detection frequencies in CNS tumors between research-
ers includes tissue integrity, fixation conditions, tissue
thickness, antibody dilution, incubation parameters, and
PCR methodologies (Scheurer et al. 2008). For example, in
the case of BKV and JCV, ultrasensitive nested PCR has
been shown to have a sensitivity of ten genomes per viral
copy (Bogdanovic et al. 1994). In the case of HHV-6, up to
fivefold difference in detection sensitivity has been reported
in a multicenter comparison among various PCR method-
ologies including nested PCR (Flamand et al. 2008).
Unfortunately, in many cases, specific viral load quantifi-
cation has not been performed with regard to CNS clinic
specimens and the theoretical copy number sufficient to
modify disease known. Another explanation for discrep-
ancies of viral detection frequency is geographic distribu-
tions of latent CNS infections. However, given the
widespread seropositivity worldwide, this seems less likely
and difficult to prove unless viral genomic sequences are
studied for region-specific polymorphisms. Since the CNS
is a potential reservoir for many latent neurotropic viruses,
it is difficult to assign causation by detection alone.
Unfortunately, there has been no investigation of the
frequency of viral genomic or antigen detection in a large
diverse cohort of normal brain by serial anatomic section-
ing to assess for anatomic tropism. This information is
paramount to determine whether viral associations with
CNS tumors are related to specific viral anatomic or cellular
tropism versus a more global reactivation phenomenon
associated with malignancy in general. For instance, in the
case of JCV, it has been recently reported that JCV genomic
segments but not proteins are present normal-appearing
brain in a small series (Perez-Liz et al. 2008). Finding
differences in genomic quantity or protein expression
between CNS tumors and non-tumor CNS controls is
critical in the establishment of a potential link between
chronic viral infection and malignancy. Since many of the
viruses establish latency in cells of hematopoetic origin, it
is difficult without ISH or IHC methodologies to accurately
confirm that positive PCR studies are exclusively of CNS
origin. It is possible that propagation of viral macro-
molecules into the CNS could come via lymphocytes as
suggested in the case of CMV by the high CMV detection
in sera of patients with GBM (Mitchell et al. 2008).
In terms of animal models of neuro-oncogenesis BKV,
SV40, and JC have all been shown to induce a number of CNS
tumors in animal models, many of them correlating with the
corresponding histological subtypes detected in human prima-
ry CNS tumors. For instance, BKV has been shown to induce
ependymoma and choroid plexus papilloma in hamsters
(Barbanti-Brodano et al. 1998, 2004; Tognon et al. 2003)
and has been detected in the corresponding subtypes in
humans with high frequency (Negrini et al. 1990; Martini et
al. 1996). Using the same animal model system, JCV
inoculated intra-cerebrally induced mostly medulloblastoma
in greater than 80% (Walker et al. 1973), suggesting that there
may be a neuro-oncologic viral tropism. To date, JCV is the
only polyomavirus able to induce CNS tumors in non-human
primates. Following injection of JCV in squirrel monkeys,
astrocytic tumors developed following a latency of 14–
36 months (London et al 1978, 1983) and contained both
integrated JCV DNA and expressed TAg protein (Miller et al.
1984; Major et al. 1984). These observations correlate with
the detection of JCV DNA and TAg in human tumors that
shows a predominance of JCV in CNS tumors of glial origin
(Table 2). In the case of the herpesviruses, it is unclear
whether the lack of malignant transformation in cell culture or
in animal models is due to technical aspects of host infectivity
versus a true lack of intrinsic neuro-oncogenic properties of
viral infection. However, this does not rule out potential
neuro-oncomodulatory mechanisms that may be contributing
to pathogenesis of disease through epigenetic mechanisms.
The JCV primate data, while not conclusive for a role in
human CNS tumorigenesis, does provide important insight
into the potential time course and mechanisms of neuro-
oncomodulation. The relatively short induction latency period
before tumor formation in squirrel monkeys, when extracted to
human lifespan is roughly between 10–20 years, suggestive of
a chronic viral persistence as opposed to primary infection. In
thecaseofacuteinfection,onewouldexpectasharpcontrastin
viral detection frequencies between adult and childhood CNS
tumors, which has not been reported for either polyomaviruses
or herpesviruses.Although,giventheveryhighseroprevalence
reported for both viruses at an early age, it would be very
difficult to associate acute infection with malignancy based on
epidemiology alone, making the concept of viral persistence
more attractive in the case of neuro-oncomodulation as
opposed to neuro-oncogenesis. In order for a virus to remain
persistent in the CNS, it must replicate without killing the host
and avoid the immunoprotective mechanisms designed to
remove it (Oldstone 2009). It is possible these exact
mechanisms used to avoid detection, may promote neuro-
oncomodulation through common molecular pathways
(Fig. 1). It is also conceivable that viral integrative mecha-
nisms may promote oncogenesis alone in the absence of viral
protein expression by insertion within key genomic regions.
A specific role of herpesviruses in primary CNS tumors
remains to be determined and is met with similar skepticism as
the polyomaviruses (Miller 2009). In the case of CMV, the
theoretical neuro-oncogenic mechanisms are in question
largely because of its inability to transform normal human
cells in culture. From a more practical standpoint, the variance
in detection frequency among researchers and the high
398 J Neuroimmune Pharmacol (2010) 5:387–403seroprevalence makes it difficult to establish a firm associa-
tion. One way to circumvent these critiques and demonstrate a
functional role for CMV and other viruses in CNS tumors is
to study the effect of treatment on disease. One example of
this is the detection of CD8+ T cells in a GBM patient that
were specific for the CMV protein pp65 following vaccina-
tion of autologous tumor lysate (Prins et al. 2008). Other clues
to CMV’s role are currently being studied in two clinical trials
in patients with GBM treated with valganciclovir and CMV
pp-65-modified dendritic cell vaccines (www.clinicaltrials.
gov), the results of which are pending. While negative results
do not necessarily exclude a role of viral infection in CNS
malignancy for a number of reasons, an improvement in
clinical outcome is supportive of such a hypothesis. Although
even a positive correlation between treatment and survival
could be explained by a secondary effect of treatment alone
unrelated to viral infection.
In order establish a more widespread support for the role of
viruses in either neuro-oncogenesis or neuro-oncomulation,
much work needs to be done. First, there must be a more
widespread cooperative validation of the multitude of PCR,
ISH, and IHC techniques used in the detection of viral
macromolecules. More importantly, the differences in viral de-
tection among researchers must be more concretely explained
through rigorous experimental approaches. Second, a better
understanding of both regional and anatomic viral tropisms in
normal brain of varying ages needs to be determined. The
early and late effects of viral infection in CNS-derived
cell lines would provide potential mechanisms of disease
that could potentially be extrapolated to human CNS
disease. Lastly, the design and implementation of new
clinical trials directed at either targeting specific viral
infections or modifying CNS neuroimmunity in favor of a
cell-mediated or humoral-specific antiviral response is need-
ed. Ultimately, a more thorough understanding of the neuro-
immunology of CNS tumors is necessary to move the
emerging field of neuro-viro-oncology forward.
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